Insights about some real gainers from healthcare segment, in the recent trading session are depicted underneath:

Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN)’s shares skyrocketed 88.98% and is now trading at $2.22, soon after a pharmaceutical company that specializes in research, development, manufacturing and distribution of a variety of narcotics and pain-administration products, declared its financial and operational results for the quarter ended December 31, 2014.

Second Quarter 2015 Highlights:

Proceeds in the second quarter rose 85% year over year to $6.4 million while cost of sales reduced 20% year over year to $1.6 million. Gross profit for the second quarter was $4.8 million, representing a 75% gross margin, and a raise of 233% as contrast to the same quarter last year.

• Net profit for the second quarter was $0.6 million instead of a net loss of $1.9 million for the same quarter last year.
• Net cash generated from operating activities for the six months ended December 31, 2014 was $3.4 million contrast to the use of $2.8 million cash in operations for the period ended December 31, 2013.
• Basic and diluted revenue per ordinary share were both $0.01 for the second quarter as contrast to net loss of ($0.04) per basic and diluted share for the same quarter last year.

Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN), a specialty pharmaceutical company, researches, develops, manufactures, and distributes various narcotic, pain-administration, and addiction treatment pharmaceutical products primarily in the People’s Republic of China.

Shares of CorMedix, Inc. (NYSEMKT:CRMD), jumped nearly 19.61% and is now trading at $4.33, hitting new 52-week high of $4.42. With recent incline, the year-to-date (YTD) performance reflected a 89.53% incline above last year. During the past month the stock gained 53.40%, bringing three-month performance to 136.60% and six-month performance to 73.21%. The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).

A pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, formerly on January 29, declared that the U.S. Food and Drug Administration (FDA) has designated the company’s lead product candidate, Neutrolin® Catheter Lock Solution, as a Qualified Infectious Disease Product (QIDP) for oncology, hemodialysis and intensive care unit patients, where catheter-related blood stream infections and clotting can be life-threatening.

The QIDP designation will make Neutrolin eligible to benefit from certain incentives as offered under the Generating Antibiotic Incentives Now (GAIN) program. These incentives comprise FDA priority review, eligibility for fast-track status and, if ultimately approved by the FDA, Neutrolin would be eligible for an additional five-year extension of Hatch-Waxman patent exclusivity.

CorMedix, Inc. (NYSEMKT:CRMD), is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix’s first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients counting neonates, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications.

Celsion Corp. (NASDAQ:CLSN), surged 13.00% and is now trading at $3.13, soon after a fully-integrated oncology company focused on the development of a high potential portfolio of innovative cancer treatments, presented clinical and preclinical data demonstrating the safety, biological activity and clinical benefits of GEN-1, its DNA-based immunotherapy, as a single agent in advanced platinum-resistant and recurrent ovarian cancer patients, at the Molecular Medicine TRI-Conference in San Francisco. These data provide support for advancing GEN-1 into clinical development in the front-line setting. The Company also declared that the U.S. Food and Drug Administration (FDA) has accepted, without comment, its planned Phase 1 dose-escalation clinical trial of GEN-1 in combination with the standard of care in neo-adjuvant ovarian cancer, which is predictable to commence in mid-2015 at five to six U.S. clinical centers.

Celsion Corp. (NASDAQ:CLSN), is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, counting directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, presently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer.

Shares of the MEI Pharma, Inc. (NASDAQ:MEIP), gained 9.52% & is now trading at $5.52, The stock has the beta value of 1.36, and its volatility for the week is 6.62%, while for the month it is 5.89%. The company has the market capitalization of $167.83M. The mean recommendation of analysts for this stock is 1.40.(where 1=Buy, 5=Sale).

MEI Pharma, Inc. (NASDAQ:MEIP), an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally accessible histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia.